Releasing full data at a conference is typically the norm. I really don't see a big deal with this. Besides, even if the company did release the final results now, do you really think it would have any real effect when the release of Lympro and the Orphan designation news did nothing to generate interest in the stock? It is clear that only certain news or events will have the potential to positively move this stock. Nothing the company has done in 2014 has been capable of moving the stock forward at all.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links
My Agenda: To see Amarantus prosper so I can make a nice return on my investment.